Global Consensus Position Statement on the Use of Testosterone Therapy for Women

@article{Davis2019GlobalCP,
  title={Global Consensus Position Statement on the Use of Testosterone Therapy for Women},
  author={Susan R. Davis and Rodney J Baber and Nick Panay and Johannes Bitzer and S Cerdas P{\'e}rez and Rakibul M. Islam and Andrew M. Kaunitz and Sheryl A Kingsberg and Irene Lambrinoudaki and James H. Liu and Sharon J. Parish and JoAnn V. Pinkerton and Janice Rymer and James A Simon and Linda Vignozzi and Margaret E Wierman},
  journal={Climacteric},
  year={2019},
  volume={22},
  pages={429 - 434}
}
Global Consensus Position Statement on the use of Testosterone Therapy for Women Susan R. Davisa,p,, Rodney Baberb,o, Nicholas Panayc,p, Johannes Bitzerd,q, Sonia Cerdas Pereze,r, Rakibul M. Islama,p, Andrew M. Kaunitzf,s, Sheryl A. Kingsbergg,t, Irene Lambrinoudakih,u, James Liui,s, Sharon J. Parishj,v, JoAnn Pinkertonk,t, Janice Rymerl,w, James A. Simonm,v, Linda Vignozzin,q, Margaret E. Wiermano,x 

Testosterone supplementation in women: When, why, and how

In this roundtable for OBG Management, several experts discuss this position statement on testosterone therapy for women as well as the overall clinical advantages and drawbacks of using testosterone in women.

International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women

This clinical practice guideline provides standards for safely prescribing testosterone to women with HSDD, including identification of appropriate patients, dosing, and monitoring, and builds on a recently published comprehensive meta-analysis and the Global Position Statement endorsed by numerous societies.

Testosterone therapy and other treatment modalities for female sexual dysfunction.

TTh is effective to treat FSD in postmenopausal women and more data is required to evaluate the long-term safety data on the effects of TTh on cardiovascular health, breast health, cognitive function, and the musculoskeletal system in women.

Use of Testosterone in Postmenopausal Women.

  • S. Davis
  • Medicine, Biology
    Endocrinology and metabolism clinics of North America
  • 2021

International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women

This clinical practice guideline provides standards for safely prescribing testosterone to women with HSDD, including identification of appropriate patients, dosing, and monitoring, and builds on a recently published comprehensive meta-analysis and the Global Position Statement endorsed by numerous societies.

The testosterone prescribing practice of BMS menopause specialists

Ask menopause experts from around the UK to see if a consensus could be reached about good prescribing practice and the method and results as discussed below may be helpful in future recommendations and guidance.

Testosterone use in postmenopausal women

Quality evidence data of clinical trials favors the use of transdermal testosterone in postmenopausal women with female sexual dysfunction causing distress, and short-term treatment periods have been shown to be effective and safe in postwomen with hypoactive sexual desire disorder/dysfunction.

Androgen therapy for women after menopause.

  • K. MarkoJ. Simon
  • Medicine, Biology
    Best practice & research. Clinical endocrinology & metabolism
  • 2021

Uso de testosterona en mujeres: un comentario sobre el consenso global sobre el uso de la terapia de testosterona para mujeres

This Position Statement was developed to provide clear guidance as to which women might benefit from testosterone therapy; to identify symptoms, signs, and certain conditions for which the evidence does not support the prescription of testosterone; to explore areas of uncertainty, and to identify any prescribing practices that have the potential to cause harm.
...

References

SHOWING 1-10 OF 32 REFERENCES

Toward excellence in testosterone testing: a consensus statement.

To ensure highly accurate testosterone testing that will result in improved diagnosis, treatment, and prevention of disease through the use of standardized assays, a series of recommendations were agreed upon.

Toward a More Evidence-Based Nosology and Nomenclature for Female Sexual Dysfunctions-Part III.

Circulating Androgen Levels and Self-Reported Sexual Function in Women

No single androgen level is predictive of low female sexual function, and the majority of women with low dehydroepiandrosterone sulfate levels did not have low sexual function.

Clinical review: The benefits and harms of systemic dehydroepiandrosterone (DHEA) in postmenopausal women with normal adrenal function: a systematic review and meta-analysis.

Evidence warranting low confidence suggests that DHEA administration does not significantly impact sexual symptoms or selected metabolic markers in postmenopausal women with normal adrenal function.

Female Sexual Dysfunction-Medical and Psychological Treatments, Committee 14.

Toward a More Evidence-Based Nosology and Nomenclature for Female Sexual Dysfunctions-Part II.

Sexual well-being after menopause: An International Menopause Society White Paper

The process of care for female sexual well-being following menopause is reviewed, from initially approaching the discussion of FSD, to identifying clinical signs and symptoms, and ultimately determining the best available biopsychosocial therapies.